Literature DB >> 15661388

Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.

Pere-Joan Cardona1, Isabel Amat, Sergi Gordillo, Virginia Arcos, Evelyn Guirado, Jorge Díaz, Cristina Vilaplana, Gustavo Tapia, Vicenç Ausina.   

Abstract

Reduction of colony forming units by rifampicin-isoniazid therapy given 9-17 weeks post-infection was made more pronounced by immunotherapy with a vaccine made of fragmented Mycobacterium tuberculosis cells detoxified and liposomed (RUTI), given on weeks 17, 19 and 21 post-infection, in the murine model of tuberculosis in C57BL/6 and DBA/2 inbred strains. RUTI triggered a Th1/Th2 response, as demonstrated by the production of IgG1, IgG2a and IgG3 antibodies against a wide range of peptides. The histological analysis did not show neither eosinophilia nor necrosis, and granulomatous infiltration was only slightly increased in C57BL/6 mice when RUTI was administered intranasally.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661388     DOI: 10.1016/j.vaccine.2004.09.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.

Authors:  Gillian L Beamer; Joshua Cyktor; David K Flaherty; Paul C Stromberg; Bridget Carruthers; Joanne Turner
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

2.  Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Shaobin Shang; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Marcela Henao-Tamayo; Laurel Hascall-Dove; David Ackart; Ian M Orme; Diane J Ordway; Randall J Basaraba
Journal:  Vaccine       Date:  2012-01-11       Impact factor: 3.641

3.  Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Michael L Pinn; Sandeep Tyagi; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2011-05-20       Impact factor: 5.790

Review 4.  Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Authors:  Houda Boukhebza; Nadine Bellon; Jean Marc Limacher; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

5.  Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Authors:  Rhea N Coler; Sylvie Bertholet; Samuel O Pine; Mark T Orr; Valerie Reese; Hillarie Plessner Windish; Charles Davis; Maria Kahn; Susan L Baldwin; Steven G Reed
Journal:  J Infect Dis       Date:  2012-08-13       Impact factor: 5.226

Review 6.  Recent advances in the development of vaccines for tuberculosis.

Authors:  Mohamed Jawed Ahsan
Journal:  Ther Adv Vaccines       Date:  2015-05

7.  Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse.

Authors:  Olga Gil; Cristina Vilaplana; Evelyn Guirado; Jorge Díaz; Neus Cáceres; Mahavir Singh; Pere-Joan Cardona
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

8.  Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.

Authors:  Olga Gil; Ivan Díaz; Cristina Vilaplana; Gustavo Tapia; Jorge Díaz; María Fort; Neus Cáceres; Sergio Pinto; Joan Caylà; Leigh Corner; Mariano Domingo; Pere-Joan Cardona
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

9.  Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.

Authors:  Evelyn Guirado; Olga Gil; Neus Cáceres; Mahavir Singh; Cristina Vilaplana; Pere-Joan Cardona
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

Review 10.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.